A Study of LY3209590 on Low Blood Sugar in Participants With Type 2 Diabetes Mellitus

Effects of LY3209590 on Frequency and Severity of Hypoglycaemia Under Conditions of Increased Hypoglycaemic Risk Compared to Insulin Glargine in Participants With Type 2 Diabetes Mellitus

The main purpose of this study is to evaluate the effect of study drug known as LY3209590 compared to insulin glargine administered in participants with type 2 diabetes mellitus (T2DM). Side effects and tolerability will be documented. The study will last almost six months and 21 visits for each participant including screening period.

Inclusion Criteria:

• Have been diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 1 year prior to screening
• Body mass index (BMI) of 18.5 to 40.0 kilograms per meter squared (kg/m²)
• Be treated for T2DM with stable dose of metformin, a stable dose of a dipeptidyl peptidase-4 (DPP-4) inhibitor with or without metformin, or a stable dose of a glucagon-like peptide-1 (GLP-1) receptor agonist with or without metformin for at least 3 months prior to screening

Exclusion Criteria:

• Have an abnormality in the 12-lead ECG
• Have a supine blood pressure at screening
• Have alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5x upper limit of normal (ULN)
• Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (except T2DM and controlled thyroid disease), haematological, or neurological disorders
• Are receiving chronic (lasting longer than 14 consecutive days) systemic or inhaled glucocorticoid therapy
• Have an average weekly alcohol intake